Patents by Inventor Guanfeng Liu

Guanfeng Liu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230364079
    Abstract: A compound as a BTK inhibitor or an HER2 inhibitor, a preparation method therefor, and a use thereof. The compound comprises a structure as shown in formula II or a tautomer, a mesomer, a racemate, an enantiomer, a diastereomer, or a mixture form thereof, and a pharmaceutically acceptable hydrate, a solvate, or salt. The BTK protein kinase inhibitor of the present invention has strong inhibitory activity on wild-type BTK or mutated BTK (C481S), and some of the compounds have high brain permeability; the HER2 inhibitor of the present invention has good HER2 kinase inhibitory activity and high blood-brain barrier transmittance; and the compound of the present invention has good pharmacokinetic properties and a good application prospect.
    Type: Application
    Filed: July 13, 2021
    Publication date: November 16, 2023
    Applicants: CHENGDU HYPERWAY PHARMACEUTICALS CO., LTD., SHENZHEN HYPERWAY PHARMACEUTICALS CO., LTD.
    Inventors: Chunchao YUE, Guanfeng LIU, Shai LI, Jing LI, Gang CHEN, Yangtong HE, Rui ZHANG, Chenguang YUAN, Yingfu LI
  • Publication number: 20230257383
    Abstract: A compound serving as a BTK inhibitor, a preparation method therefor, and a use thereof. The compound has a structure represented by formula I, or a tautomer, a mesomer, a racemate, an enantiomer, a diastereomer or a mixture thereof, or a pharmaceutically acceptable hydrate, solvent, or salt thereof, wherein A1, A2, A3, A4, A5 and A6 are each independently selected from C—R5 and N, and at least one of those is N; and M is selected from substituted or unsubstituted saturated or heterosaturated hydrocarbyl, substituted or unsubstituted unsaturated cyclic group or heterocyclyl, and substituted or unsubstituted monocyclic, bicyclic, or tricyclic aryl or heteroaryl. The provided BTK protein kinase inhibitor has strong inhibition for wild BTK and mutated BTK (C481S), has good pharmacokinetic properties, and has good application prospects.
    Type: Application
    Filed: July 13, 2021
    Publication date: August 17, 2023
    Applicants: CHENGDU HYPERWAY PHARMACEUTICALS CO., LTD., SHENZHEN HYPERWAY PHARMACEUTICALS CO., LTD.
    Inventors: Chunchao YUE, Guanfeng LIU, Shai LI, Jing LI, Gang CHEN, Yangtong HE, Rui ZHANG, Chenguang YUAN, Yingfu LI
  • Patent number: 11473735
    Abstract: A light bulb includes a bulb shell, a light source, a driver, a head housing and a bottom switch. The light source is enclosed by the bulb shell for emitting a light through the bulb shell. The driver converts an external power to a driving current supplied to the light source. The head housing has an Edison cap. The head housing is coupled to the bulb shell. The driver is enclosed by the head housing. The Edison cap is plugged to an Edison socket for receiving the external power source. The bottom switch is disposed on the bottom of the Edison cap for changing a setting of the driver.
    Type: Grant
    Filed: July 17, 2021
    Date of Patent: October 18, 2022
    Assignee: XIAMEN LEEDARSON LIGHTING CO., LTD
    Inventors: Xiaobo Chen, Shenggan Wang, Mingyan Fu, Guanfeng Liu, Liangliang Cao, Mingli Wei, Ran Gao, Zhipeng Zhao
  • Publication number: 20220042658
    Abstract: A light bulb includes a bulb shell, a light source, a driver, a head housing and a bottom switch. The light source is enclosed by the bulb shell for emitting a light through the bulb shell. The driver converts an external power to a driving current supplied to the light source. The head housing has an Edison cap. The head housing is coupled to the bulb shell. The driver is enclosed by the head housing. The Edison cap is plugged to an Edison socket for receiving the external power source. The bottom switch is disposed on the bottom of the Edison cap for changing a setting of the driver.
    Type: Application
    Filed: July 17, 2021
    Publication date: February 10, 2022
    Inventors: Xiaobo Chen, Shenggan Wang, Mingyan Fu, Guanfeng Liu, Liangliang Cao, Mingli Wei, Ran Gao, Zhipeng Zhao
  • Patent number: 10793576
    Abstract: The present invention provides a compound having a structure shown in formula (I) or an isomer, pharmaceutically acceptable solvate, or salt thereof. The compound is used as a Bruton's tyrosine kinase inhibitor, and has a higher inhibitory activity against BTK and less adverse effects.
    Type: Grant
    Filed: February 20, 2017
    Date of Patent: October 6, 2020
    Assignees: CHENGDU BRILLIANT PHARMACEUTICAL CO., LTD., CHENGDU HIGHBRED PHARMACEUTICAL CO., LTD.
    Inventors: Yingfu Li, Haoxi Huang, Guanfeng Liu, Tonghui Chen, Junfeng Ren, Zhonghai Su
  • Publication number: 20190315758
    Abstract: The present invention provides a compound having a structure shown in formula (I) or an isomer, pharmaceutically acceptable solvate, or salt thereof. The compound is used as a Bruton's tyrosine kinase inhibitor, and has a higher inhibitory activity against BTK and less adverse effects.
    Type: Application
    Filed: February 20, 2017
    Publication date: October 17, 2019
    Inventors: Yingfu Li, Haoxi Huang, Guanfeng Liu, Tonghui Chen, Junfeng Ren, Zhonghai Su